About Nephros (OTCMKTS:NEPH)
Nephros, Inc. (Nephros) is a commercial-stage medical device and commercial products company that develops and sells high performance liquid purification filters and hemodiafiltration (HDF) systems. The Company's filters, ultrafilters, are primarily used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate, and used in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas. The Company has approximately two product lines: HDF Systems and Ultrafiltration Products. Its products in HDF modality deliver therapy for End Stage Renal Disease (ESRD) patients. It offers ultrafilters for customers in hospitals and other healthcare facilities for filtration of water to be used for patient washing and drinking as an aid in infection control. The filters also produce water that is suitable for wound cleansing, cleaning of equipment used in medical procedures and washing of surgeons' hands.
Industry, Sector and Symbol
Industry MED PRODS
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$3.81 million
Price / Sales7.20
Price / CashN/A
Book Value$0.04 per share
Price / Book12.08
Return on Equity-238.35%
Return on Assets-74.71%
Nephros (OTCMKTS:NEPH) Frequently Asked Questions
What is Nephros' stock symbol?
Nephros trades on the OTCMKTS under the ticker symbol "NEPH."
How were Nephros' earnings last quarter?
Nephros, Inc. (OTCMKTS:NEPH) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.01) earnings per share for the quarter. The company earned $0.92 million during the quarter. Nephros had a negative return on equity of 238.35% and a negative net margin of 21.24%. View Nephros' Earnings History.
When will Nephros make its next earnings announcement?
Who are some of Nephros' key competitors?
Some companies that are related to Nephros include Arch Therapeutics (ARTH), BIOLASE (BIOL), Reshape Lifesciences (RSLS), Capricor Therapeutics (CAPR), PURE Bioscience (PURE), BioSig Technologies (BSGM), Imprimis Pharmaceuticals (IMMY), Rewalk Robotics (RWLK), Cesca Therapeutics (KOOL), Microbot Medical (MBOT), InVivo Therapeutics (NVIV), Dynatronics (DYNT), Valeritas (VLRX), Cellectar Biosciences (CLRB), Check Cap (CHEK), Neovasc Inc (US) (NVCN), Neurometrix (NURO) and SenesTech (SNES).
Who are Nephros' key executives?
Nephros' management team includes the folowing people:
- Daron Evans, President, Chief Executive Officer
- Andrew Astor, Chief Financial Officer
- Paul A. Mieyal Ph.D., Director
- Malcom C. Persen, Director
- Moshe Pinto, Director
- Arthur H. Amron, Independent Director
Has Nephros been receiving favorable news coverage?
Media headlines about NEPH stock have been trending positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nephros earned a coverage optimism score of 0.30 on Accern's scale. They also assigned media coverage about the company an impact score of 46.96 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Nephros?
Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nephros' stock price today?
One share of NEPH stock can currently be purchased for approximately $0.48.
How big of a company is Nephros?
Nephros has a market capitalization of $25.56 million and generates $3.81 million in revenue each year. The company earns $-800,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Nephros employs 15 workers across the globe.
How can I contact Nephros?
Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.
MarketBeat Community Rating for Nephros (NEPH)MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Nephros (OTCMKTS:NEPH) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Nephros (OTCMKTS:NEPH) Earnings History and Estimates Chart
Nephros (OTCMKTS NEPH) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/19/2018|| || || || || || || || |
|11/9/2017||Q3 2017||($0.01)||$0.92 million||View||N/A|
|8/8/2017||Q2 2017||($0.01)||$0.86 million||View||N/A|
|5/9/2017||Q1 2017||($0.01)||$0.73 million||View||N/A|
|3/20/2017||Q4 2016||($0.01)||$0.75 million||View||N/A|
|8/8/2016||Q3 2016||($0.01)||$0.51 million||View||N/A|
|5/11/2016||Q1 2016||($0.02)||$0.59 million||View||N/A|
|3/30/2016||Q4 2015||($0.02)||$0.51 million||View||N/A|
|11/10/2015||Q3 2015||($0.02)||$0.32 million||View||N/A|
|8/10/2015||Q2 2015||($0.06)||$0.57 million||View||N/A|
|5/15/2015||Q1 2015||($0.02)||$0.54 million||View||N/A|
|4/15/2015||Q4 2014||($0.22)||$0.34 million||View||N/A|
|11/14/2014||Q3 2014||($0.03)||$0.49 million||View||N/A|
|8/14/2014||Q2 2014||($0.03)||$0.44 million||View||N/A|
|5/14/2014||Q1 2014||($0.04)||$0.47 million||View||N/A|
|3/28/2014||Q4 2013||($0.07)||$0.23 million||View||N/A|
|11/14/2013||Q3 2013||($0.03)||$0.42 million||View||N/A|
|8/13/2013||Q2 2013||($0.05)||$0.58 million||View||N/A|
|5/8/2013||Q1 2013||($0.10)||$0.52 million||View||N/A|
Nephros (OTCMKTS:NEPH) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.02 EPS
Dividend History for Nephros (OTCMKTS:NEPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Nephros (OTCMKTS NEPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.00%
Nephros (OTCMKTS NEPH) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/9/2018||Andrew Astor||CFO||Buy||5,000||$0.48||$2,400.00|| |
|12/4/2017||Andrew Astor||CFO||Buy||18,333||$0.50||$9,166.50|| |
|9/6/2017||Daron Evans||Insider||Buy||29,580||$0.24||$7,099.20|| |
|8/28/2017||Andrew Astor||CFO||Buy||10,000||$0.27||$2,700.00||186,709|| |
|8/22/2017||Daron Evans||Insider||Buy||4,000||$0.25||$1,000.00|| |
|8/11/2017||Andrew Astor||CFO||Buy||20,000||$0.26||$5,200.00||186,666|| |
|8/11/2017||Daron Evans||Insider||Buy||70,000||$0.26||$18,200.00|| |
|6/9/2017||Daron Evans||Insider||Buy||21,461||$0.26||$5,579.86|| |
|5/19/2017||Daron Evans||Insider||Buy||30,000||$0.26||$7,800.00|| |
|12/7/2016||Daron Evans||Insider||Buy||4,069||$0.32||$1,302.08||339,428|| |
|12/5/2016||Daron Evans||Insider||Buy||10,620||$0.34||$3,610.80||329,339|| |
|12/1/2016||Daron Evans||Insider||Buy||41,530||$0.32||$13,289.60||284,140|| |
|8/31/2015||Daron Evans||CEO||Buy||44,175||$0.57||$25,179.75||169,759|| |
|8/20/2015||Daron Evans||CEO||Buy||51,500||$0.53||$27,295.00||125,584|| |
Nephros (OTCMKTS NEPH) News Headlines
Nephros (OTCMKTS:NEPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Nephros (OTCMKTS NEPH) Stock Chart for Monday, March, 19, 2018